Abstract Details

Title Early vs Delayed Treatment with Teriflunomide 14 mg Results in Reduced Risk of Disability Progression in Patients with MS

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 021

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Paul W. O'Connor, MD PRESENTER	No disclosure on file
	No disclosure on file
Pascal L. Rufi (Sanofi, Research and Development)	Mr. Rufi has nothing to disclose.
Philippe Truffinet, MD (Sanofi)	Dr. Truffinet has received personal compensation for serving as an employee of Sanofi.

��ɫ��